Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Combining physiological, environmental and locational sensors for citizen-oriented health applications.

Huck JJ, Whyatt JD, Coulton P, Davison B, Gradinar A.

Environ Monit Assess. 2017 Mar;189(3):114. doi: 10.1007/s10661-017-5817-6. Epub 2017 Feb 16.

2.

Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).

Huck JJ, Zhang M, Mettetal J, Chakravarty A, Venkatakrishnan K, Zhou X, Kleinfield R, Hyer ML, Kannan K, Shinde V, Dorner A, Manfredi MG, Shyu WC, Ecsedy JA.

Mol Cancer Ther. 2014 Sep;13(9):2170-83. doi: 10.1158/1535-7163.MCT-14-0027. Epub 2014 Jun 30.

3.

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.

Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, Wysong DR, Janowick DA, Hyer ML, Leroy PJ, Gershman RE, Silva MD, Germanos MS, Bolen JB, Claiborne CF, Sells TB.

Clin Cancer Res. 2011 Dec 15;17(24):7614-24. doi: 10.1158/1078-0432.CCR-11-1536. Epub 2011 Oct 20.

4.

MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.

Huck JJ, Zhang M, McDonald A, Bowman D, Hoar KM, Stringer B, Ecsedy J, Manfredi MG, Hyer ML.

Mol Cancer Res. 2010 Mar;8(3):373-84. doi: 10.1158/1541-7786.MCR-09-0300. Epub 2010 Mar 2.

5.

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ, Ray ET, Sells TB, Stringer B, Stroud SG, Vos TJ, Weatherhead GS, Wysong DR, Zhang M, Bolen JB, Claiborne CF.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11. Epub 2007 Feb 23.

Supplemental Content

Support Center